HIV Env trimer-liposome vaccine elicits cross-neutralizing antibodies in non-human primates
Updated
Updated · Nature.com · Apr 29
HIV Env trimer-liposome vaccine elicits cross-neutralizing antibodies in non-human primates
4 articles · Updated · Nature.com · Apr 29
In 12 rhesus macaques, all six given trimer-liposomes developed tier-two cross-neutralization, with serum from all six neutralizing over 49% of a 67-virus panel.
Researchers isolated 58 monoclonal antibodies, and cryo-EM showed antibodies from four macaques targeted the HIV Env apex similarly to human broadly neutralizing antibody PG9.
The findings mark a substantial advance toward an HIV vaccine, though the work remains preclinical and HIV's diversity means further optimisation and eventual human testing are still needed.
Will this primate breakthrough finally lead to a functional cure for humans with HIV?
After success in primates, when will human trials for this new HIV vaccine begin?
Could new HIV variants escape the antibodies generated by this promising new vaccine?
What are the hurdles to making this complex HIV vaccine globally affordable and accessible?
Could Scripps' DNA scaffolds make this new vaccine even more potent and precise?
Can this vaccine's 'B cell education' strategy be used against other viruses like influenza?